迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688192 迪哲医药

已收盘 11-22 15:00:01

{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":45.1,"timestamp":1732258801000,"preClose":47.91,"halted":0,"volume":2567732,"delay":0,"floatShares":123000000,"shares":416000000,"eps":-2.0143,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.81,"latestTime":"11-22 15:00:01","open":48.36,"high":48.36,"low":45.1,"amount":119000000,"amplitude":0.068,"askPrice":45.24,"askSize":3,"bidPrice":45.1,"bidSize":77,"shortable":0,"etf":0,"ttmEps":-2.0143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":47.91,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":52.7,"lowLimit":43.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":415653120,"pbRate":43.75,"roa":"--","roe":"--","epsLYR":-2.72,"committee":0.585799,"marketValue":18746000000,"floatMarketCap":5551000000,"peRate":-22.389911,"changeRate":-0.0587,"turnoverRate":0.0209,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。","afterMarket":{"amount":0,"volume":0,"close":45.1,"buyVolume":0,"sellVolume":0,"time":1732260839464,"indexStatus":"已收盘 11-22 15:30:00","preClose":47.91}},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2485893702","title":"迪哲医药-U跌5% 10家券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2485893702","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485893702?lang=zh_cn&edition=full","pubTime":"2024-11-22 14:36","pubTimestamp":1732257387,"startTime":"0","endTime":"0","summary":"11月22日，迪哲医药-U股价大幅下跌，截至14点36分，迪哲医药-U下跌5.03%，报45.50元/股，成交9515万元，换手率1.65%。资金动向截止发稿，迪哲医药-U获得主力净流入197万元，其中超大单流出652万元，大单流入850万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。最新财报显示，今年三季报，迪哲医药-U实现营业收入3.38亿元，同比增长743.97%，净利润为-5.58亿元，同比增长32.63%，基本每股收益为-1.35元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122143651a24d2909&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122143651a24d2909&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2485072601","title":"迪哲医药-U大涨 论坛聚焦医药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2485072601","media":"智选洞察","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485072601?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:43","pubTimestamp":1732153396,"startTime":"0","endTime":"0","summary":"11月21日，迪哲医药-U股价大幅上涨，截至09点43分，迪哲医药-U上涨5.23%，报49.10元/股，成交6342万元，换手率1.07%，振幅5.81%。资金动向截止发稿，迪哲医药-U获得主力净流出620万元，其中超大单流出93万元，大单流出525万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121094341a249f48d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121094341a249f48d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688192","BK0239"],"gpt_icon":0},{"id":"2484873461","title":"迪哲医药-U涨5% 生物医药论坛召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2484873461","media":"智选洞察","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484873461?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:34","pubTimestamp":1732066468,"startTime":"0","endTime":"0","summary":"11月20日，迪哲医药-U股价大幅上涨，截至09点34分，迪哲医药-U上涨5.05%，报45.95元/股，成交2053万元，换手率0.37%，振幅6.36%。资金动向截止发稿，迪哲医药-U获得主力净流出12万元，其中超大单流入84万元，大单流出96万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120093443abd09c22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120093443abd09c22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","161726","688192","BK0239"],"gpt_icon":0},{"id":"2482703301","title":"迪哲医药：源头创新 小分子创新药迈向全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703301","media":"国泰君安","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482703301?lang=zh_cn&edition=full","pubTime":"2024-11-12 00:00","pubTimestamp":1731340800,"startTime":"0","endTime":"0","summary":"舒沃替尼、戈利昔替尼陆续步入收获期，早期管线充沛，潜力十足，首次覆盖，给予增持评级。公司立足源头创新，打造具备全球竞争力的差异化管线，核心产品舒沃替尼、戈利昔替尼陆续步入收获期。舒沃替尼突破肺癌难治突变，全球市场渐入收获期。戈利昔替尼取得PTCL 领域新突破，提供治疗新选择。戈利昔替尼于2024 年6 月在中国市场获批上市，进一步提供业绩增量，在海外亦有望迈向商业化阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2482956225","title":"天风证券：给予迪哲医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2482956225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482956225?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:15","pubTimestamp":1731302130,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松,曹文清近期对迪哲医药进行研究并发布了研究报告《舒沃替尼向FDA递交上市申请，国际化取得重要进展》，本报告对迪哲医药给出买入评级，当前股价为48.6元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家；过去90天内机构目标均价为54.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100012442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","688192"],"gpt_icon":0},{"id":"2482095219","title":"医药早参丨迪哲医药肺癌药舒沃替尼向FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2482095219","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482095219?lang=zh_cn&edition=full","pubTime":"2024-11-11 08:17","pubTimestamp":1731284240,"startTime":"0","endTime":"0","summary":"每经记者：陈星每经编辑：张海妮｜ 2023年11月11日 星期一 ｜NO.1 迪哲医药肺癌药舒沃替尼向FDA递交上市申请11月8日，迪哲医药宣布，自主研发的肺癌靶向药舒沃替尼向美国食品药品监督管理局递交新药上市申请，这是首个向FDA递交上市申请的中国原创肺癌靶向药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111081855a22a9359&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111081855a22a9359&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","159938","BK0239"],"gpt_icon":0},{"id":"2481108432","title":"迪哲医药向FDA递交舒沃哲新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2481108432","media":"市场资讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481108432?lang=zh_cn&edition=full","pubTime":"2024-11-08 20:54","pubTimestamp":1731070440,"startTime":"0","endTime":"0","summary":"11月8日，迪哲医药宣布，公司已于近日向美国食品药品监督管理局递交舒沃哲的新药上市申请，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒检测确认的，存在表皮生长因子受体20号外显子插入突变的局部晚期或转移性非小细胞肺癌的成人患者。舒沃哲成为首款向FDA递交新药上市申请的中国源创肺癌靶向药。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-08/doc-incvkiwh3666139.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-08/doc-incvkiwh3666139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2481469651","title":"迪哲医药：向美国FDA递交舒沃替尼新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2481469651","media":"21世纪经济报道","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481469651?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:44","pubTimestamp":1731051840,"startTime":"0","endTime":"0","summary":"南方财经11月8日电，迪哲医药公告，公司已向美国食品药品管理局（FDA）递交舒沃替尼片的新药上市申请，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒检测确认，存在表皮生长因子受体（EGFR）20号外显子插入突变（Exon20ins）的局部晚期或转移性非小细胞肺癌（NSCLC）的成人患者。舒沃替尼成为首款向美国FDA递交新药上市申请的中国源创肺癌靶向药。该申请基于一项评估舒沃替尼针对经治EGFR Exon20ins NSCLC患者疗效和安全性的国际多中心注册临床研究“悟空1B”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108154456a2234485&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108154456a2234485&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2481145236","title":"迪哲医药(688192.SH)：已向FDA递交舒沃替尼新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2481145236","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481145236?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:43","pubTimestamp":1731051782,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司已向美国食品药品管理局(FDA)递交舒沃替尼片的新药上市申请(New Drug Application，NDA)，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒检测确认，存在表皮生长因子受体(EGFR)20号外显子插入突变(Exon20ins)的局部晚期或转移性非小细胞肺癌(NSCLC)的成人患者。舒沃替尼成为首款向美国FDA递交新药上市申请的中国源创肺癌靶向药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2481469921","title":"迪哲医药-U11月08日遭主力抛售878万元 环比增加174.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481469921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481469921?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:19","pubTimestamp":1731050381,"startTime":"0","endTime":"0","summary":"11月08日, 迪哲医药-U股价跌1.62%，报收46.88元，成交金额1.54亿元，换手率2.63%，振幅3.36%，量比0.84。迪哲医药-U今日主力资金净流出878万元，连续4日净流出，上一交易日主力净流出320万元，今日环比增加174.38%。近一年数据显示，该股主力连续4日净流出后，次日下跌概率为83.33%，平均跌幅为1.14%。该股近5个交易日下跌2.62%，主力资金累计净流出1994万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入405万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108154246abacc07e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108154246abacc07e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2481272306","title":"迪哲医药：11月5日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2481272306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481272306?lang=zh_cn&edition=full","pubTime":"2024-11-06 17:34","pubTimestamp":1730885666,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月6日迪哲医药发布公告称公司于2024年11月5日召开业绩说明会。的销售增长，迪哲医药前三季度收入大幅增长。问：在刚刚结束的2024医保谈判上，迪哲医药两款产品均进场谈判。的国家医保谈判工作，具体谈判情况请关注有关部门公示或公告。公司定位于参与全球化竞争，正积极准备海外新药上市申请事宜，后续公司将及时公告相关进展。迪哲医药主营业务：创新药的研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600030879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2481508876","title":"EGFR造富神话再现，有公司营收同比增7倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2481508876","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481508876?lang=zh_cn&edition=full","pubTime":"2024-11-05 19:47","pubTimestamp":1730807253,"startTime":"0","endTime":"0","summary":"今年前三季度，迪哲医药营收达到3.38亿元，同比增长743.97%，公司亏损缩减32.63%，达到5.58亿元。迪哲医药目前两款产品上市，一个是EGFR抑制剂舒沃替尼，另一个JAK1抑制剂戈利昔替尼。仅EGFR抑制剂，奥希替尼、阿美替尼、贝福替尼续约或新增适应症，瑞齐替尼则是首次试图进入医保目录。EGFR抑制剂的竞争已经白热化，尤其是19、21外显子的竞争。今年艾力斯单季度营收同比增速分别在168.65%、76.56%和59.73%，增速已经有明显放缓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105201123a2187430&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105201123a2187430&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192"],"gpt_icon":0},{"id":"2480768680","title":"11月1日迪哲医药-U涨8.55%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480768680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480768680?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:17","pubTimestamp":1730449069,"startTime":"0","endTime":"0","summary":"证券之星消息，11月1日迪哲医药-U涨8.55%，收盘报48.14元，换手率5.24%，成交量6.45万手，成交额3.05亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共37家，其中持有数量最多的公募基金为鹏华医药科技股票A。鹏华医药科技股票A目前规模为25.32亿元，最新净值1.0542，较上一交易日下跌0.34%，近一年下跌6.95%。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100029580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","09939","688192","159938","BK1515","BK1574"],"gpt_icon":0},{"id":"2480776019","title":"迪哲医药-U大幅上涨 获融资净买入465万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480776019","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480776019?lang=zh_cn&edition=full","pubTime":"2024-11-01 09:37","pubTimestamp":1730425070,"startTime":"0","endTime":"0","summary":"11月01日，迪哲医药-U股价大幅上涨，截至09点37分，迪哲医药-U上涨5.16%，报46.64元/股，成交2927万元，换手率0.52%，振幅6.38%。资金动向截止发稿，迪哲医药-U获得主力净流入34万元，其中超大单流出59万元，大单流入93万元。融资融券方面，迪哲医药-U10月30日获得融资净买入465万元，当日该股融资余额为5266万元，当较前一日增加9.71%，实现4连增；该股融券余额为35万元，融券余量为0.77万股，比上日减少52.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101093839a20548f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101093839a20548f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2480018242","title":"迪哲医药（688192）10月31日主力资金净买入440.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480018242","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480018242?lang=zh_cn&edition=full","pubTime":"2024-11-01 08:24","pubTimestamp":1730420677,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月31日收盘，迪哲医药报收于44.35元，下跌1.79%，换手率2.47%，成交量3.04万手，成交额1.36亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入408.59万元，融资偿还787.6万元，融资净偿还379.01万元。迪哲医药主营业务：创新药的研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100009758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2479277464","title":"迪哲医药(688192)9月30日股东户数0.86万户，较上期增加1.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479277464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479277464?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:11","pubTimestamp":1730365884,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迪哲医药披露，截至2024年9月30日公司股东户数为8642.0户，较6月30日增加169.0户，增幅为1.99%。在化学制药行业个股中，迪哲医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.1万户。从股价来看，2024年6月30日至2024年9月30日，迪哲医药区间涨幅为18.95%，在此期间股东户数增加169.0户，增幅为1.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100033806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2479103915","title":"迪哲医药三季度亏损2.14亿元 同比增长32.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479103915","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479103915?lang=zh_cn&edition=full","pubTime":"2024-10-31 10:13","pubTimestamp":1730340787,"startTime":"0","endTime":"0","summary":"截至三季度末，公司总资产16.43亿元，较上年度末增长9.8%；归母净资产为4.28亿元，较上年度末下降49.5%。文章来源：财中社迪哲医药三季度亏损2.14亿元 同比增长32.1%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031103937ab87dbd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031103937ab87dbd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2479798452","title":"社保基金三季度末持仓市值近1900亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479798452","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479798452?lang=zh_cn&edition=full","pubTime":"2024-10-31 06:54","pubTimestamp":1730328874,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0251","001267","BK0201","BK0183","BK0066","BK0188","688376","BK0214","600031","BK0005","IE00BZ08YR35.GBP","BK0239","BK0196","BK0224","BK0229","BK0277","688439","BK0000","BK0039","600426","IE00BZ08YT58.USD","BK0028","IE0005HP3H50.USD","688717","IE00BZ08YS42.EUR","688192","BK0037"],"gpt_icon":0},{"id":"2478227120","title":"迪哲医药：业绩说明会定于11月5日举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2478227120","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478227120?lang=zh_cn&edition=full","pubTime":"2024-10-28 15:46","pubTimestamp":1730101600,"startTime":"0","endTime":"0","summary":"每经AI快讯，迪哲医药 10月28日晚间发布公告称，公司2024年第三季度业绩说明会定于2024年11月05日下午13:00-14:00，以上证路演中心网络互动的形式进行。出席本次业绩说明会的人员有：董事长兼总经理首席执行官张小林，董事会秘书兼财务总监吕洪斌，独立董事姜斌，王学恭，朱冠山，张昕。截至发稿，迪哲医药市值为192亿元。道达号“个股趋势”提醒：1. 近30日内无机构对迪哲医药-U进行调研。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028154803ab7a9128&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028154803ab7a9128&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2478713486","title":"迪哲医药-U10月25日主力资金流入1150万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478713486","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478713486?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:19","pubTimestamp":1729840785,"startTime":"0","endTime":"0","summary":"10月25日, 迪哲医药-U股价涨3.70%，报收46.00元，成交金额1.39亿元，换手率2.49%，振幅5.91%，量比1.01。迪哲医药-U今日主力资金净流入1150万元，连续5日净流入，上一交易日主力净流入894万元，今日环比增加28.64%。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为40.00%，平均涨幅为7.57%。该股近5个交易日上涨4.55%，主力资金累计净流入4932万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出4224万元，其中净流出天数为5日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153958ab72c598&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153958ab72c598&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","stockEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.2081},{"period":"6month","weight":0.1535},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0575}],"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","perCapita":"14242股","boardName":"医药制造业","registeredCapital":"41565万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。公司研发管线均为小分子创新药，所有产品均享有全球权益，并采用全球同步开发的模式。","serverTime":1732346822759,"listedPrice":52.58,"stockholders":"8642人(较上一季度增加1.99%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}